quarta-feira, 7 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 18, 2026

Big Short Steve Eisman Favors Schwab, Cites Robinhood's Lack Of 'Margin For Error' Amid Bitcoin-Led Crypto Slide

View original at finance.yahoo.com
Big Short Steve Eisman Favors Schwab, Cites Robinhood's Lack Of 'Margin For Error' Amid Bitcoin-Led Crypto Slide Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Robinhood trades at a 2026 PE multiple over 30 times, while Charles Schwab commands a significantly lower 17 times PE, creating a stark valuation disparity with no margin for error

    80% confidence

  • A not insignificant portion of Robinhood's customers invest in crypto, and the crypto slump is directly impacting Robinhood's performance

    80% confidence

  • Retail investors continue to buy every dip in the broader market, but this strategy may not hold for assets facing structural headwinds and competitive pressures when valuations offer little cushion

    80% confidence

  • The renewed decline in crypto prices is a major factor hurting platforms like Robinhood and Coinbase

    80% confidence

  • As long as crypto prices keep going down, so will the stock price of Coinbase

    80% confidence

  • The forward PE for HOOD stood at 29.85, as compared to SCHW's 16.31 ratio

    80% confidence

  • Robinhood will not go up until at least crypto stabilizes

    80% confidence

  • Robinhood has no margin for error given its current trajectory and lofty valuation

    80% confidence

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Big Short Steve Eisman Favors Schwab, Cites Robinhood's Lack Of 'Margin For Error' Amid Bitcoin-Led Crypto Slide — Source | Via News | pt.VIA.NEWS